Cleveland Clinic TAPS DYANIA HEALTY uses AI to speed up clinical trials
This week, the Cleveland Clinic announced that it will expand Dyania Health’s AI platform among its businesses to accelerate clinical trial recruitment and hope to enable patients to access beneficial therapies faster.
Founded in 2019, Dyania, New Jersey, is dealing with one of the most time-consuming tasks of healthcare: manual chart reviews.
“Today, clinicians have to screen years of patient history and piece together information scattered in medical records to draw conclusions. In clinical trials, the scale of thousands of patients, a process that will take several years for human reviewers to complete,” explained Eirini Schlosser, CEO of Dyania.
Dyania's platform can automate this work and determine the eligibility of patients to participate in clinical trials. The system not only provides a one-time reading, but also continuously reviews updated and altered records to determine whether patients meet trial inclusion and exclusion criteria.
Schlosser added that the system is unique because it is developed for deep medicine and technical rigorous.
“Before large language models became mainstream, Diana quietly built and annotated a large number of data sets in R&D to capture the real clinical environment and nuances in electronic medical records to train us [large language model named] she declared.
While other healthcare AI developers may focus on polishing interfaces, Dyania focuses on “engines under the engine.”
The Cleveland Clinic started using Dyania’s technology in early 2024 to launch pilot programs in oncology, cardiology and neurology.
In the melanoma trial, Dyania's AI identified eligible patients with 96% accuracy in 2.5 minutes, while the study nurses exceeded 400 minutes. In the cardiology trial, the platform analyzed 1.2 million records and found twice as eligible within a week, just as traditional methods did in three months.
Lara Jehi, chief research information officer at Cleveland Clinic, said the deployment had been successful on multiple levels and called for a decision to be “obvious.”
“This technology is powerful and has reached all of our expected success milestones for accuracy, ease of use and speed of execution. The end-user experience is very positive – our investigators interacted well with the Dyania team and our research coordinator was happy to move their efforts from the sieved charts to the charts that interact directly with the patients,” she said.
She also noted that patients from regional practices, often excluded from research opportunities, can have more access to clinical trials.
For Yeshi, the partnership between Cleveland Clinic and Diana is a step in the right direction for medical innovation. She noted that slow patient recruitment is one of the biggest obstacles, involving slow and expensive clinical research processes.
“Scientific advances in medicine are designed to make people healthier, faster, and better treat them. If the drug is not tested through clinical trials to ensure safety and effectiveness. Now, this process now takes nearly a decade, and on average costs billions of dollars,” she said.
By automating one of the most arduous steps in clinical research, the Cleveland Clinic and Diana hope to speed up the path from discovery to treatment.
Photos: djelics, Getty Images
